Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07252765

Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice

The objective of this observational study is to characterize the patient profile and nutritional treatment patterns of individuals with type 2 diabetes (T2D) or drug-induced diabetes who present with malnutrition, or are at risk of it, and who are prescribed a diabetes-specific oral nutritional supplement (ONS) that is high in calories and protein and contains soluble fiber.

Participants will complete a series of questionnaires during visits 1 and 3.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

Loading trial locations.

About this study

  • Background and Rationale This study focuses on patients with type 2 diabetes mellitus (T2D) who also present with malnutrition or are at risk of developing malnutrition. These conditions negatively affect clinical and functional outcomes, increasing the likelihood of complications and hospitalizations. The use of diabetes-specific oral nutritional supplements (ONS)-characterized by a high caloric and protein content and enriched with soluble fiber-may contribute to improving clinical status, nutritional parameters, and quality of life. Nevertheless, current evidence from real-world clinical practice remains limited and heterogeneous.
  • Primary Objective To characterize the clinical and nutritional profile, as well as the nutritional treatment patterns, of patients with T2D and malnutrition or at risk of malnutrition who are prescribed a diabetes-specific ONS.
  • Secondary Objectives

To assess changes in glycemic and metabolic control.

To evaluate the nutritional and functional impact of the ONS.

To analyze healthcare resource utilization and associated costs.

To estimate patient adherence, compliance, and satisfaction with the prescribed ONS.

To assess quality-of-life outcomes over a 6-month follow-up period.

  • Exploratory Objective To explore changes in muscle mass using nutritional ultrasound.
  • Study Design

Multicenter, prospective, real-world evidence (RWE) study.

Conducted across 12 hospitals in Spain.

Three scheduled visits: baseline (V1), 3-month follow-up (V2), and 6-month final visit (V3).

  • Study Population A total of 334 adult patients with T2D and either nutritional risk or malnutrition, all of whom are prescribed a diabetes-specific ONS.
  • Collected Variables

Sociodemographic: age, sex, education level, etc.

Clinical and anthropometric: weight, muscle mass, comorbidities.

ONS-related: product name, dosage, duration, modifications, palatability.

Nutritional requirements: daily caloric, protein, fat, and carbohydrate needs.

Healthcare resource utilization: hospital admissions, emergency visits, specialist consultations, and diabetes medication adjustments.

Metabolic profile: HbA1c, fasting glucose, lipid panel, albumin, total protein, hemoglobin, liver enzymes, eGFR, and CRP.

Functional assessment: SARC-F scale, handgrip strength, bioelectrical impedance analysis (BIA), nutritional ultrasound, and Timed Up and Go test.

Patient-reported outcomes: NutriQoL® quality-of-life questionnaire, satisfaction survey, treatment adherence questionnaire, and ONS palatability scale.

  • Data Management and Analysis Data will be managed by Outcomes'10 and analyzed using STATA v.14. Descriptive and comparative analyses will be conducted to address the primary and secondary objectives. All data will be reviewed and pseudonymized to ensure patient confidentiality.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients diagnosed with type 2 diabetes (T2D) or drug-induced diabetes
  • Patients at nutritional risk according to MUST or presenting malnutrition according to GLIM criteria.
  • Patients requiring a diabetes-specific oral nutritional supplement (ONS) that is high-calorie, high-protein, and contains soluble fiber in real-world clinical practice, and who have been prescribed such a supplement within the previous 7 days.
  • Patients able to provide informed consent and complete the study questionnaires.

Exclusion criteria

  • Patients participating in other studies or clinical trials related to malnutrition, or who, in the investigator's opinion, may alter the course of the study.
  • Patients currently receiving or expected to receive other types of nutritional interventions involving supplements (oral or otherwise) or non-conventional feeding methods (e.g., feeding tubes).
  • Patients with a history of metabolic/endocrine diseases (other than diabetes) or any other condition causing liver or kidney failure, defined as ALT > 3x ULN or eGFR < 30 ml/min/1.73 m², and according to the investigator's judgment.
  • Patients expected to undergo any surgical intervention or require hospitalization due to a condition unrelated to the study during the study period.
  • Patients with other conditions that, in the investigator's opinion, may interfere with adherence to the intervention or with study procedures.

Treatment and study plan

Primary outcomes

  1. Descriptive of study population

    Time frame: Baseline visit (V1)

    Descriptive information of the population at V1

Secondary outcomes

  1. Percentage change of blood test parameters

    Time frame: From enrollment to end of treatment at 24 weeks

    Changes in blood test measures will be compared

  2. Percentage of patients with improvement in the nutritional status

    Time frame: From enrollment to end of treatment at 24 weeks

    Changes in GLIM or MUST classifications

  3. Associated cost at 6-month follow-up

    Time frame: From enrollment to end of treatment at 24 weeks

    They will be estimated by multiplying the number of units used by their unit cost (derived from eSalud and Botplus databases). Unit: Number of events; euros (€)

  4. Adherence with prescribed oral nutritional supplement (ONS)

    Time frame: From enrollment to end of treatment at 24 weeks

    Participants will be categorized as compliant (≥80% consumption) or non-compliant (<80%).

  5. Change in functional status of participants over time

    Time frame: From enrollment to end of treatment at 24 weeks

    Changes between visits in SARC-F scale categories

  6. Change in NutriQoL® quality-of-life score

    Time frame: From enrollment to end of treatment at 24 weeks

    Patients will be classified according to a quality-of-life category (excellent, good, acceptable, poor, very poor). Test total scoring values.

  7. Patient satisfaction of the ONS product at 6 months

    Time frame: From enrollment to end of treatment at 24 weeks

    Responses to the satisfaction questionnaires will be summarized as number and percentage of participants selecting each category at V3.

  8. Patient palatability of the ONS product at 6 months

    Time frame: From enrollment to end of treatment at 24 weeks

    Responses to the palatability questionnaires will be summarized as number and percentage of participants selecting each category at V3.

  9. Health resource use

    Time frame: From enrollment to end of treatment at 24 weeks

    Frequencies of treatment changes, administration route, specialist consultations, and hospitalizations will be recorded and quantitative variables (treatment dose, treatment duration, number and days of hospitalization, consultations) will be summarized using mean ± SD.

  10. Change in nutritional status

    Time frame: From enrollment to end of treatment at 24 weeks

    It will be estimated according to GLIM or MUST classification

  11. Percentage change in BMI

    Time frame: From enrollment to end of treatment at 24 weeks

    Weight and height will be combined to report BMI in kg/m2

  12. Maximum prehensile strenght value

    Time frame: From enrollment to end of treatment at 24 weeks

    Probe: handgrip test by using a hand dynamometer

  13. 30" chair test

    Time frame: From enrollment to end of treatment at 24 weeks

    Test: a patient will have to stand-up and sit-down as maximim number of times in 30", from a chair, with both arms crossed in the chest.

  14. Impedancimetry values

    Time frame: From enrollment to end of treatment at 24 weeks

    Test: bioimpedance

Other outcomes

  1. Nutritional status at molecular level

    Time frame: From enrollment to end of treatment at 24 weeks

    Test: nutritional (morphofunctional) ecography

Study contacts

Contact information is provided by the study sponsor or research team.

Mercedes Blanco Naveira, Medical Adviser. MD

CONTACT

[email protected]

+34 628 237 634

Sponsors and collaborators

Lead sponsor

Outcomes'10

Network

Collaborators

  • Nestlé Health Science Spain

Registry information

Official study title

Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice. STARLIGHT Study

Acronym: STARLIGHT

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 28, 2025
Registry last updated
Jan 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.